Info

Northwest Biotherapeutics, Inc. is a development-stage biotechnology company focused on discovering, developing, and commercializing immunotherapy products that generate and enhance immune system responses to effectively treat cancer. The Company's approach in developing cancer therapies utilizes its capability in the biology of dendritic cells (DC), which are a type of white blood cells that activate the immune system. Northwest Biotherapeutics has two basic technology platforms applicable to cancer therapeutics: dendritic cell-based cancer vaccines, which is called DCVax, and monoclonal antibodies for cancer therapeutics. Its DCVax dendritic cell-based cancer vaccine program is its main technology platform. It combines a dendritic cells with a patient’s own cancer-related biomarkers, or off-the-shelf antigens, to induce immune responses against a patient’s cancer cells.(Source: 10-K)